Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
amitriptyline – tricyclic antidepressant used to treat separation anxiety, excessive grooming dogs and cats; amlodipine – calcium channel blocker used to decrease blood pressure; amoxicillin – antibacterial; apomorphine – emetic (used to induce vomiting) artificial tears – lubricant eye drops used as a tear supplement
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1 , VEGFR2 and VEGFR3 kinases.
The best known standards and protocols used by DICOM are: [29] DICOM Makes use of the OSI network model. It uses the 2 network protocols on which the Internet is based and which allow data transfer, TCP / IP, and the HTTP hypertext transfer protocol. Additionally DICOM has its own MIME content type. DICOM uses other protocols such as DHCP, SAML ...
The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...
Brolucizumab is approved by the US Food and Drug Administration (FDA) for use in ophthalmology. [7] [8]Brolucizumab successfully completed phase III development in wet age-related macular degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to week 48.
Brentuximab vedotin [6] consists of the chimeric monoclonal antibody brentuximab (cAC10, which targets the cell-membrane protein CD30) linked with maleimide attachment groups, cathepsin-cleavable linkers (valine-citrulline), and para-aminobenzylcarbamate spacers to three to five units of the antimitotic agent monomethyl auristatin E (MMAE, reflected by the 'vedotin' in the drug's name). [7]